VHH in

Cell Therapies

Small, stable and robust, VHH offer an attractive construct for incorporation as targeting agents in cell therapies.

VHH can also be easily engineered with carefully designed affinities, valencies and specificities to meet a variety of therapeutic needs, enabling refined cell targeting and modes of action while also minimising off-target toxicity.

Advantages of

VHH in Cell Therapy

Lower Immunogenicity than scFv

VHH domains are less immunogenic than single chain constructs such as ScFv because of their high homology with human VH genes and absence of exposed hydrophobic regions. The level of immunogenicity can have an important impact on the long-term persistence of the infused cells and, consequently, on the antitumor response.

Increased Specificity

VHH antibodies are small in size and stable. They can be formatted into bi-and multi-specifics, creating dual targeting Chimeric Antigen Receptors that bind two antigens which are co-expressed on malignant tissue for T-cell activation.

Access to Solid Tumours

Multi-valent VHH Chimeric Antigen Receptors allow enhanced targeting of heterogeneous tumours, improved tissue penetration of re-directed T-cells and co-stimulation of T-cells to enhance cytotoxicity and reduce on target off-tumour toxicity.


VHH in CAR-T Resources

Clinical landscape and applications of single domain VHH antibodies for optimisation of next generation T-cell immunodirection therapies

This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities. 

Using Llamda-VHH to optimize T-cell mediated immunotherapies

In this webcast, speakers will introduce the unique benefits of the VHH antibodies generated from the hLlamdA synthetic library and summarize how single domain VHH antibodies can be engineered to tune their binding selectivity and specificity for antigen targeting and be applied to optimize the next generation of these important new therapeutic modalities.

Partnerships at Isogenica

Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.